Comparison of the platelet functions measured by platelet function analyzer-100 and verify-now systems in patients with stable coronary artery disease Kararli koroner arter hastalarinda platelet function analyzer-100 ve verify-now sistemleri kullanilarak ölçülen trombosit i̇şlevlerinin karşilaştirilmasi


PAMUKÇU B., Çimen O. A., ASLANGER K. E., Gölcük E., Önür I., Oflaz H.

Nobel Medicus, cilt.7, sa.1, ss.79-83, 2011 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 7 Sayı: 1
  • Basım Tarihi: 2011
  • Dergi Adı: Nobel Medicus
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.79-83
  • Anahtar Kelimeler: 'PFA-100', 'verify-now', Aspirin resistance, Coronary heart disease, Platelet function
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objective: The aim of our study was to compare the two methods 'Platelet Function Analyzer (PFA)- 100' and 'VerifyNow' systems which are used in the evaluation of the efficiency of antiplatelet therapy in patients with stable coronary heart disease. Material and Method: Fourty-two patient who were on follow-up from our outpatients clinic with the diagnosis of stable coronary heart disease treated with regular aspirin therapy were enrolled in the study. Blood samples were studied in a hour by the 'PFA-100' and 'VerifyNow' systems. In the 'PFA-100' system measurements were performed with the collagen and epinephrine (Col/Epi) and collagen and adenosine diphosphate cartridges. A closure time of <186s with Col/Epi cartridges was accepted as aspirin resistance. Aspirin resistance was defined as having an ARU>550 IU with the aspirin cartridges by the 'Verify Now' system. Baseline characteristics, therapy regimens and platelet function test were compared. A correlation analysis was also performed between the two platelet function test. Results: Aspirin resistance was present in 14.2% and 11.9% of the patients by the 'PFA-100' and 'VerifyNow' respectively. Demographic fidigs were similar between the aspirin resistant and sensitive patients. We determined a corelation coefficient of r=0.60 between the two methods (p=0.706). Although the aspirin resistance prevalence was similar with both methods, the concordance was low because different patients were found resistant to aspirin by the methods used (~%17). Conclusion: In our study we reached different platelet function results by the two point of care methods. A low concordance was found between the 'PFA-100' and 'Verify Now' methods. Discordance between the platelet function assays is still an handicap in the routine monitorization of the antiplatelet therapy.